



1/20/09 | Press Release

DAVA announces the launch of Zidovudine Oral Solution

Fort Lee, New Jersey, January 20, 2009 – DAVA Pharmaceuticals, Inc. (“DAVA”) is proud to announce the introduction of Zidovudine Oral Solution 50mg/5ml. Zidovudine Oral Solution is an AA-rated version of GlaxoSmithKline’s Retrovir® Oral Solutions. DAVA’s Zidovudine Oral Solution is immediately available for delivery.

DAVA Pharmaceuticals Inc., a specialty pharmaceuticals company, is focused on developing and marketing a broad portfolio of pharmaceutical products. DAVA is aggressively building its product portfolio through a combination of acquisitions, strategic alliances, in-licensing transactions, partnerships and development. DAVA’s headquarters is in Fort Lee, New Jersey. For further information, please visit DAVA’s website located at www.davapharma.com.